SCHEMBL334925

SCHEMBL334925

O=C=Nc1ccc(F)c(Cl)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.68
TDP1 Q9NUW8 1/20 0.68
IDO1 P14902 7/20 0.46
ITGB3 P05106 1/20 0.46
ITGAV P06756 1/20 0.46
CYP3A4 P08684 2/20 0.44
TRPA1 O75762 1/20 0.44
TSHR P16473 2/20 0.41
EGFR P00533 1/20 0.37
TDO2 P48775 2/20 0.36
SLC2A1 P11166 1/20 0.36
MAOB P27338 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KAT2B Q92831 2/20 0.34
PIN1 Q13526 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29454784 1.00 MAPK1 (0.68) MAPK1TDP1IDO1ITGB3ITGAV
SCHEMBL8676888 0.87 MAPK1 (0.53) MAPK1TDP1IDO1ITGB3ITGAV
SCHEMBL3831454 0.84 MAPK1 (0.68) MAPK1TDP1IDO1ITGB3ITGAV
SCHEMBL8093598 0.82 CYP3A4 (0.50) MAPK1TDP1IDO1ITGB3ITGAV
SCHEMBL161540 0.81 MAPK1 (0.52) MAPK1TDP1IDO1CYP3A4TRPA1
SCHEMBL29824353 0.81 MAPK1 (0.52) MAPK1TDP1IDO1CYP3A4TRPA1
SCHEMBL58874 0.81 MAPK1 (1.00) MAPK1TDP1ITGB3ITGAVCYP3A4
SCHEMBL29376406 0.81 MAPK1 (1.00) MAPK1TDP1ITGB3ITGAVCYP3A4
SCHEMBL418944 0.80 CYP3A4 (0.58) MAPK1TDP1CYP3A4TRPA1TSHR
SCHEMBL1018986 0.80 ITGB3 (0.46) MAPK1TDP1IDO1ITGB3ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 US claimed
CN-119431706-A Fatigue-resistant polyurethane elastomer and preparation method and application thereof 万勋科技(深圳)有限公司 2025-02-14 CN claimed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US claimed
EP-4171569-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF Council of Scientific & Industrial Research (IN) 2023-05-03 EP claimed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 WO claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 US disclosed
US-20250235462-A1 NOVEL CAPSID ASSEMBLY INHIBITORS AM SCIENCES INC (KR) 2025-07-24 US disclosed
CN-119431706-A Fatigue-resistant polyurethane elastomer and preparation method and application thereof 万勋科技(深圳)有限公司 2025-02-14 CN disclosed
US-20250009742-A1 NOVEL CAPSID ASSEMBLY INHIBITORS META-IMMUNE, INC. (KR) 2025-01-09 US disclosed
CN-113923988-B Substituted arylmethyl ureas and heteroarylmethyl ureas, analogs thereof, and methods of using the same 爱彼特生物制药公司 2024-12-13 CN disclosed
EP-4416142-A1 NOVEL CAPSID ASSEMBLY INHIBITORS AM Sciences Inc (KR) 2024-08-21 EP disclosed
EP-4416150-A1 NOVEL CAPSID ASSEMBLY INHIBITORS AM Sciences Inc (KR) 2024-08-21 EP disclosed
EP-0156091-A1 Beta-oxo-alpha-carbamoyl-pyrrolepropionitriles, processes for their preparation, pharmaceutical compositions comprising these compounds and their therapeutic use CIBA-GEIGY AG (CH) 1985-10-02 EP disclosed
EP-0153127-A2 N-aryl-3-aryl-4,5-dihydro-1H-pyrazole-1-carboxamides, processes for their production, insecticidal compositions containing them and methods for combatting insects ROHM AND HAAS COMPANY (US) 1985-08-28 EP disclosed
US-4470930-A Preparation of nuclear chlorinated aromatic compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1984-09-11 US disclosed
US-4207317-A ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS CIBA-GEIGY CORPORATION (US) 1980-06-10 US disclosed
US-4131751-A PHENYLENE, PLANT GROWTH REGULATORS BASF AKTIENGESELLSCHAFT (DE) 1978-12-26 US disclosed
US-4046909-A Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants MCNEIL LABORATORIES, INCORPORATED (US) 1977-09-06 US disclosed
US-3998958-A Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants MCNEIL LABORATORIES, INCORPORATED (US) 1976-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250235462-A1 NOVEL CAPSID ASSEMBLY INHIBITORS ZC3HAV1, GTF3C3, ZC3HAV1L MAPK1 2616/4885TDP1 1201/4885IDO1 2952/4885
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC MAPK1 2282/4885TDP1 985/4885IDO1 2054/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 MAPK1 2409/4885TDP1 1533/4885IDO1 2796/4885
US-20250009742-A1 NOVEL CAPSID ASSEMBLY INHIBITORS ZC3HAV1, ZC3HAV1L, MAVS MAPK1 2676/4885TDP1 1195/4885IDO1 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.